Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-FMT versus placebo after antibiotic pretreatment in Parkinson's disease
jRCTs031240344Active, not recruiting
- Sponsor
- Metagen Therapeutics, Inc.
- Start
- Dec 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of allogeneic fecal microbiota and Placebo-COD Research Private Ltd in Parkinson's disease (PD) (2 arms), sponsored by Metagen Therapeutics, Inc. Primary endpoint: Change in MDS-UPDRS total score at 8 weeks after FMT. Started Dec 2024; status: active, not recruiting.
02
Drugs
allogeneic fecal microbiotaPlacebo-COD Research Private Ltd
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCTs031240344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240344.